Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: LNA043 Clear all
Terminated Phase 2 Interventional Results available

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

NCT04864392
View directory record Official record
Conditions
Osteoarthritis
Interventions
LNA043, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.

NCT03275064
View directory record Official record
Conditions
Osteoarthritis
Interventions
LNA043, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • La Mesa, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 3, 2026, 12:15 AM EDT
Completed Phase 1 Interventional

First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement

NCT02491281
View directory record Official record
Conditions
Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
Interventions
LNA043, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 3, 2026, 12:15 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

NCT04814368
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
canakinumab, LNA043, Placebo to canakinumab
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
La Mesa, California • Clearwater, Florida • Sunrise, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 3, 2026, 12:15 AM EDT